Apricus Biosciences (APRI) Stock Research, Analysis & News

Quick Analysis on Apricus Biosciences (APRI) Stock as of October 20, 2017

Previous Closing Price $1.90 is above 50 day moving average of $1.77
Previous Closing Price $1.90 is above 200 day moving average of $1.37
The Stock pays no dividend
The closing price $1.90 is more than 77.89% away from its one year target price of $3.38
Current Short Ratio 3.14 is great than 1
EBITDA $-10.05M is negative
It is a very small cap stock with market cap of $23.27M
(See more information about Apricus Biosciences (APRI) Stock below)

Apricus Biosciences (APRI) Stock Profile Summary

NexMed, Inc. engages in designing and developing pharmaceutical products based on its patented NexACT drug delivery technology. The NexACT drug delivery technology is designed to enhance the delivery of an active drug to improve therapeutic outcomes and reduce systemic side effects that accompany oral and injectable medications. The companys proprietary topical nail solution, NM100060, is a Phase III clinical trial product for the treatment of onychomycosis (nail fungal infection). Its products also include Vitaros, a Phase III clinical trial topical alprostadil-based cream treatment for patients with erectile dysfunction; and Femprox, a Phase II clinical trial alprostadil-based cream product for the treatment of female sexual arousal disorder. In addition, NexMed focuses on developing treatments for psoriasis, cancer inflammation, pain, and wound healing. Further, the company, through its subsidiary, Bio-Quant, Inc., operates as a specialty biotech contract research organization that provides services in the areas of non-good laboratory practices in vitro and in vivo contract drug discovery, as well as pre-clinical development services specializing in oncology, inflammation, immunology, and metabolic diseases. Bio-Quant, Inc. also conducts studies in the areas of in vitro and in vivo pharmacology, pharmacokinetics, and toxicology to support pre-investigational new drug enabling packages, as well as sells diagnostic kits. The company was founded in 1987 and is headquartered in San Diego, California.

Apricus Biosciences (APRI) Stock Key Statistics Research and Analysis as of October 20, 2017

Stock ExchangeNCM
Market Capitalization$23.27M
Trade Volume (Average Trading Volume)128,591 (379,295)
Price/Sales4.21
Price/Book3.70
P/E3.04
Earning/Share$0.60
Current Year EPS Estimate$-0.81
Next Year EPS Estimate$0.36
Previous Closing Price$1.90
50 Day Price Moving Average$1.77
200 Day Price Moving Average$1.37
1 yr Target Price$3.38
PEG Ratio0.00
Short Ratio3.14
EBITDA$-10.05M

Apricus Biosciences (APRI) Stock Competitor Research and Analysis

Pfizer Inc. (PFE)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Stock Research on Apricus Biosciences (APRI)

Latest Market News on Apricus Biosciences (APRI)


Click here to find the latest news on Apricus Biosciences (APRI)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Pfizer Inc. (PFE)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)